Results 81 to 90 of about 1,562,206 (187)

Impact of bronchodilator therapy on exercise tolerance in COPD

open access: yes, 2010
B AguilaniuHYLAB, Laboratory of Clinical Physiology and Exercise, Grenoble, FranceAbstract: Exercise tolerance is an important parameter in patients with COPD and a primary goal of treatment is to reduce dyspnea to facilitate physical activities and ...
B Aguilaniu
core  

WITHIN-BREATH RESPIRATORY RESISTANCE IN CHILDREN WITH POSITIVE BRONCHODILATOR RESPONSE

open access: yes, 2022
WITHIN-BREATH RESPIRATORY RESISTANCE IN CHILDREN WITH POSITIVE BRONCHODILATOR ...
A Chacko (13367877)   +5 more
core  

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

open access: yesPulmonary Therapy, 2019
Introduction To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk ...
Riju Ray   +5 more
doaj   +1 more source

Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management

open access: yesMedComm, Volume 7, Issue 10, October 2026.
A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley   +1 more source

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

open access: yesInternational Journal of COPD, 2015
Nobuyuki Horita, Takeshi Kaneko Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan Abstract: Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device ...
Horita N, Kaneko T
doaj  

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study [PDF]

open access: yes, 2009
Background: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. However, there are only limited data about the influence of GOLD severity staging on the effectiveness of ...
Jones, Paul W   +44 more
core   +2 more sources

Influence of ADRB2 variants on bronchodilator response and asthma control in a mixed population [PDF]

open access: yesJornal Brasileiro de Pneumologia
Objective: Given that b2 agonists constitute the primary treatment for asthma and that treatment response varies as a result of polymorphisms in the ADRB2 gene, we sought to investigate the associations between ADRB2 gene variants and bronchodilator ...
Pedro Augusto Silva dos Santos Rodrigues   +10 more
doaj   +1 more source

Iron and Other Metal Ions in Human Health and Disease

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients

open access: yesInternational Journal of COPD, 2020
José Luis López-Campos,1,2 Bernardino Alcázar Navarrete,3 Juan Antonio Riesco Miranda,2,4 Borja G Cosío,2,5 Juan P de-Torres,6 Bartolomé Celli,7 Carlos A Jiménez-Ruiz,8 Ciro Casanova Macario9 1Unidad Mé ...
López-Campos JL   +7 more
doaj  

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

open access: yesPulmonary Therapy, 2019
Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients.
Anthony D’Urzo   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy